In a report released yesterday by Goldman Sachs, the firm commented on Merck & Co. MRK. In the report, Goldman Sachs was mixed in its assessment.
Goldman Sachs writes, “FDA granted MRK's Victrelis a limited label excluding null responders, which represents approximately 30% of treatment experienced patients. We see the exclusion of nulls as relatively in-line given the lack of prospective P3 trials and a 25% increase in cure rate vs. IFN/RBV. However, we believe the market expectations and our forecasts assuming a 25%/75% market split favoring TVR already reflect this.”
Goldman Sachs currently has a Neutral rating on Merck & Co and a price target of $40. Shares of the company closed the trading day on Friday at $37.08, down $0.01 from the opening bell.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in